RenovoRx Stock Based Compensation To Revenue from 2010 to 2024
| RNXT Stock | USD 1.27 0.01 0.79% |
Stock Based Compensation To Revenue | First Reported 2010-12-31 | Previous Quarter 0.0 | Current Value 0.0 | Quarterly Volatility 0.0 |
Check RenovoRx financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among RenovoRx's main balance sheet or income statement drivers, such as Net Interest Income of 116.5 K, Interest Income of 64.3 K or Depreciation And Amortization of 5.1 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. RenovoRx financial statements analysis is a perfect complement when working with RenovoRx Valuation or Volatility modules.
RenovoRx | Stock Based Compensation To Revenue |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for RenovoRx Stock Analysis
When running RenovoRx's price analysis, check to measure RenovoRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RenovoRx is operating at the current time. Most of RenovoRx's value examination focuses on studying past and present price action to predict the probability of RenovoRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RenovoRx's price. Additionally, you may evaluate how the addition of RenovoRx to your portfolios can decrease your overall portfolio volatility.